Disease · HP_0025569
Polypoidal choroidal vasculopathy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Polypoidal choroidal vasculopathy. Diseases, record HP_0025569. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0025569
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Polypoidal choroidal vasculopathy
- Open Targets ID
- HP_0025569
- Highest stage of its drugs
- Phase 3, for 3 of its 11 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AFLIBERCEPT | CHEMBL1742982 | Protein | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| BROLUCIZUMAB | CHEMBL3707357 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FARICIMAB | CHEMBL4297750 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RANIBIZUMAB | CHEMBL1201825 | Antibody | Phase 2/3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| FOSBRETABULIN | CHEMBL1206232 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CONBERCEPT | CHEMBL2108313 | Protein | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PEGAPTANIB SODIUM | CHEMBL1201421 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| PEGPLERANIB SODIUM | CHEMBL3301576 | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets22
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | 7 | Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor | Phase 3 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| PGF | Placenta growth factor | 2 | Placenta growth factor inhibitor | Phase 3 | https://conductscience.org/library/genes/5228 | Drugs and targets |
| ANGPT2 | Angiopoietin-2 | 1 | Angiopoietin-2 inhibitor | Phase 3 | https://conductscience.org/library/genes/285 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Unknown | https://conductscience.org/library/genes/1719 | Drugs and targets |
| PDGFB | Platelet-derived growth factor subunit B | 1 | Platelet-derived growth factor subunit B inhibitor | Unknown | https://conductscience.org/library/genes/5155 | Drugs and targets |
| TUBA1A | Tubulin | 1 | Tubulin disrupting agent; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 1 | Tubulin disrupting agent; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 1 | Tubulin disrupting agent; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 1 | Tubulin disrupting agent; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 1 | Tubulin disrupting agent; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/112714 | Drugs and targets |
1 to 10 of 22
See all 22 targetsTrials26
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04423718 | Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye | Phase 3 | 1,011 | 2023-09-06 | Neovascular Age-Related Macular Degeneration | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT02597855 | Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy | 29 | 2016-06-17 | Polypoidal Choroidal Vasculopathy | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov | |
| NCT01884597 | Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) | Phase 1/2 | 24 | 2017-09-11 | PCV, Polypoidal Choroidal Vasculopathy | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00837330 | Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy | Phase 1/2 | 20 | 2014-06-23 | Polypoidal Choroidal Vasculopathy | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01469156 | Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy | Phase 1/2 | 20 | 2022-12-12 | Polypoidal Choroidal Vasculopathy | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00779142 | Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies | Not applicable | 2 | 2014-06-30 | Diabetic Macular Edema | METHOTREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT03128463 | Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases | 5,000 | Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, Pathological Myopia, Conbercept, Pharmacogenomic | CONBERCEPT | Its record names the disease | ClinicalTrials.gov | ||
| NCT02081339 | Cohort Study of the Clinical Course of Macular Diseases in Japanese | 1,000 | Macular Disease | AFLIBERCEPT, RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT05229237 | Conbercept for Polypoidal Choroidal Vasculopathy（START Study） | 500 | Polypoidal Choroidal Vasculopathy, Conbercept | CONBERCEPT | Its record names the disease | ClinicalTrials.gov | ||
| NCT05251636 | Adjunct Episcleral Brachytherapy for PCV | Phase 3 | 159 | Age-Related Macular Degeneration, Polypoid Choroidal Vasculopathy | AFLIBERCEPT | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 26
See all 26 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Type 1 Polypoidal Choroidal Vasculopathy vs Type 2 Polypoidal Choroidal Vasculopathy: serious adverse events | 0 of 18 | 0 of 14 | 32 | NCT02597855 | Trial comparisons |
| Ranibizumab 0.5 mg vs Ranibizumab 0.3 mg: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT00837330 | Trial comparisons |
| Control Group: Ranibizumab 0.5mg vs Ranibizumab 1.0mg or 2.0mg: serious adverse events | 0 of 5 | 0 of 15 | 20 | NCT01469156 | Trial comparisons |
Papers from its trials26
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0025569
GET https://conductscience.org/api/diseases/v1/HP_0025569/targets?page=2